Benefits investigation and verification, explained.

A benefits investigation answers one question before a specialty drug starts: what will this plan do for this patient?

Where the benefits check falls on the road to a first fill

1. The doctor prescribesDr. Moreno's office at Larchway Dermatology chooses Veltrimab for Jordan Ellis.
2. The office enrolls the patientThe form, the insurance card and a signed consent reach the hub on October 6, 2026.
3. The hub investigates the benefitsAn electronic check, a payer call, the formulary and the portal are read, reconciled and written up. This is the step this guide is about.
4. The approvals are chasedThe office submits prior authorization and asks for a step therapy exception, and the hub helps with the paperwork.
5. The specialty pharmacy shipsOnly now does the patient get the medicine, and only if the earlier steps went right.

The patient, office, plan and medicine in this example are fictional.

Four things about benefit verification that surprise newcomers

eBV, prior authorization, step therapy and copay accumulator in one line each

Fourteen terms are defined in the one-page summary.

What goes on a benefits summary: eleven values, from plan status to whether copay help counts

In shortA summary has four parts: coverage, what the patient pays, access rules and copay support. Teams collect far more than this underneath, and the eleven below are what an office needs to act. No single source reliably states all of them.

The office needs a short answer it can act on the same day. Behind it, a thorough specialist records many more details: the plan's phone number, the group, whether the provider is in network, renewal dates. The fictional hub in this guide reads about 27 values from each source. The eleven below are the ones that change what happens next, and they are the set used in this guide's example.

Field lists differ by program, and no public standard sets them. This table is our own description, using the eleven values of the fictional case.

Why the eBV, the payer call and the formulary give different answers, and how specialists decide which to trust

In shortEach source carries its own date and blind spots. An electronic check is quick and can be stale. A call is current and rests on one person's reading. A formulary is the plan's own document and says nothing about this patient. The usual method is to compare value by value, ask why any two differ, prefer the newest dated source, and record the choice.

Five sources behind one benefits summary, and the weakness of each

Our own description. No public study compares these sources across payers. The nearest we found are vendor statements, listed in section 12.

The electronic query has a long history. HIPAA, the federal law behind health data standards and privacy, names the X12 270 and 271 transactions as the national standard for eligibility questions (270) and answers (271) for medical care.3 Plans that follow the operating rules must return certain details, but the rules federally adopted in the 2025 edition of the regulations are the Phase I and Phase II sets from 2011.4

CAQH, the group behind those rules, wrote in its 2024 report that an updated set would require plans to return prior authorization and tiered benefit information, and that a federal rule to adopt it was on the agenda.5 That update is absent from the edition we read, so for now it is fair to expect a 271 answer to say nothing about PA.

Provider offices run these checks constantly. Medical plans and providers made 31.5 billion eligibility and benefit checks in 2023, which CAQH counts as 51% of all the administrative transactions it tracks. Health plans reported 96% of them as fully electronic.5 That number sounds as if the problem is solved. A routine check confirms that a person is covered for an office visit. A specialty benefits investigation asks whether one named drug needs approval this week.

CAQH puts the provider's cost per check at $8.57, $4.46 and $2.00 for the same three modes.5

A worked comparison: six values agree, four differ, one needs confirming

Take the case from the top of this page. The electronic check ran at 4:24 pm on October 6, using data dated June 15. The call ran at 9:12 am on October 7. The plan's formulary carries a July 1 update.

1. Line them up. For each value, write down what each source says, and where. On tier: "Tier 4" from the eBV, "as of July 1 it moved from tier 4 to tier 5" from the rep at 02:18 into the call, and "Tier 5" in the formulary.
2. Ask why any two differ. Three sources were dated, and the oldest is the eBV, so a mid-year update explains the tier. The $50 copay is simply the old tier's amount. Prior authorization and step therapy arrived with the move.
3. Prefer the newest dated source, and say so. A newer source usually wins. It does not always: a rep can misread a screen, and the formulary may describe a different plan under the same payer. If the rep and the document conflict, call back and ask for the effective date.
4. Treat silence as silence. The eBV says nothing about copay help. "Not reported" must stay "not reported" on the worksheet, and a person should ask.
5. Record the choice. Who chose which value, from which source, and what it overrode. That record answers the office's question next month.

Checking the PA criteria against what the office sent

A good investigation goes one step further and reads the plan's criteria against the hub record. In the example, the portal lists four criteria. Jordan meets three on the documents in hand: a diagnosis of moderate-to-severe plaque psoriasis (code L40.0), 14% of body surface affected, against a 10% threshold, and 16 weeks of methotrexate against a 12-week minimum.

The fourth, a trial of one preferred biologic (a drug made from living cells), is unmet. So the office should ask for a step therapy exception with the medical reason. Nobody at the hub says the plan will approve it. That decision belongs to the plan and the doctor.

Which coverage rules bind which kind of plan: commercial, Medicare, Medicaid and employer self-funded

In shortThe first thing a benefits specialist must know is what kind of plan this is, because it decides which law applies, whether copay help is allowed and how fast the plan must answer. The best-known federal PA rule, CMS-0057-F from the Centers for Medicare & Medicaid Services (CMS), leaves drugs out. Most workers are in self-funded plans that state law reaches poorly.

Five plan types follow. Medicare Part D is Medicare's prescription drug benefit, delivered through private plans.6 Medicare Advantage is a private, Medicare-approved plan that bundles Medicare coverage. Part B, which covers services from doctors and other providers, also pays for some drugs. A self-funded employer pays for its workers' care from its own funds, and a fully insured employer buys a policy from an insurer.7

A simplification, and our own. Ask counsel about any single plan. Coverage policy monitoring across plans is covered in depth in our payer coverage policy tracking guide.

What HIPAA says about a hub calling a plan: covered entities, authorization and minimum necessary, as of November 2026

In shortHIPAA binds plans, clearinghouses, most providers and those who work on their behalf. A drug maker is not on that list merely for making drugs, so the plan and the office generally need the patient's written authorization to share details with its hub. That authorization has required contents, and it changes how the "minimum necessary" rule applies. All section references below are to the 2025 edition of title 45, as of October 1, 2025.

Nearly every statement people make about HIPAA and hubs turns on who is covered. The rule covers three kinds of covered entity: a health plan, a health care clearinghouse, and a health care provider who transmits health information electronically in a covered transaction (45 CFR 160.103).16 A business associate is someone who handles protected health information on behalf of a covered entity. A hub run for a specialty pharmacy may be one. A hub run for a drug maker has a different footing, so read the contract.

A covered entity may disclose information for its own payment work, and for the payment activities of another covered entity or a provider that receives it (164.506(c)).17 A drug maker's benefit check is neither of those, on our reading, which is why most hub enrollment forms carry a signed authorization.

Six things a valid HIPAA authorization must contain

The left column follows 45 CFR 164.508(c)(1); the right column is our illustration, and your counsel writes the form.18 The form also needs the required statements in (c)(2), on revoking it, on conditioning and on redisclosure. A covered entity may not generally condition treatment or payment on signing (b)(4), and the patient may revoke in writing (b)(5).18

The standards are moving too. For retail pharmacy drugs, the eligibility standard is the Telecommunication Standard from NCPDP, the National Council for Prescription Drug Programs: version D.0 through August 14, 2027, either D.0 or F6 until April 14, 2028, and F6 alone from then on (162.1202).3

Medicare Part D sponsors, the companies that offer the plans, must also run a real-time benefit tool for prescribers, showing cost sharing, alternatives and any utilization rules, and from January 1, 2027 it has to follow a named federal standard (42 CFR 423.160(b)(5)).20,21 Those tools answer the prescriber at the moment of prescribing, and the text we read does not extend them to a hub.

We read HHS's rules in the Code of Federal Regulations and the Federal Register. HHS's own guidance pages were not read. Laws outside HIPAA may also apply to a hub, including state health data and privacy laws, because they can reach data HIPAA does not. Ask counsel which apply to you.

Copay accumulators and maximizers: how a $0 year turns into $5,000, and why the federal rule is unsettled

In shortA drug maker's copay card can pay a commercial patient's share. An accumulator takes that money and does not count it toward the deductible. A maximizer spreads it across the year so that it is all used up. Rules differ by state and plan, the federal position has been unsettled since a 2023 court ruling, and an electronic check usually will not tell you which one applies.

The money is large. IQVIA data cited in the trade press puts manufacturer copay assistance at $21.4 billion in 2024, with $7 billion retained by insurers and pharmacy benefit managers (PBMs).23 The article calls that 37%, while $7 billion of $21.4 billion is about 33% by our division. We did not read IQVIA's own report, so treat both shares with care.

Plan sponsors, the employers and others who pay for coverage, see that as a saving: in one survey, 62% of commercial sponsors in 2025 called copay assistance a good way to help them save money, up from 28% in 2018.1 Patient groups see a double payment.

The arithmetic: what one accumulator does to one patient's year

Suppose a plan like Jordan's in 2027: a $2,500 deductible, then 30% capped at $250 a fill, and 13 fills a year. Add two assumptions the case does not state: the drug costs $6,000 a fill, and the copay card pays up to $6,000 a year.

• When help counts. Fill 1 costs the patient $2,750 ($2,500 of deductible plus the $250 cap), and the card pays it. Twelve later fills cost $250 each, or $3,000. The total is $5,750, inside the card's $6,000. The patient pays $0.
• When help does not count. The plan ignores the card's payments, so fill 1 and fill 2 each cost $2,750, and the card pays both, leaving $500. Fill 3 costs $2,750 too: the card pays $500 and the patient pays $2,250. Only that $2,250 counts, leaving $250 of deductible. Fill 4 costs $500: the last $250 of deductible plus the $250 cap. Fills 5 to 13 cost $250 each, or $2,250. The patient pays $5,000, and the card's $6,000 is gone by the third fill.

A maximizer has its own arithmetic. Spread evenly over 13 fills, the same $6,000 card is $461.54 a fill. The patient pays $0 if enrolled in the plan's program, and much more if not. On a summary, the value that matters is the action: enroll in the plan's program, in this order, by this date.

Why the patient's outcome turns on one line in the summary

Published evidence is limited and old, but it points one way. One study followed 15 self-insured employers, which pay for care from their own funds, that started an accumulator in January 2017.

After 10 months, patients in health savings account plans had 233 fewer autoimmune drug fills per 1,000 patients than comparable patients in PPO plans, which charge less for in-network care. They also had 20 percentage points more discontinuation, meaning they stopped the drug, and 12 percentage points fewer days covered, the share of days the patient had drug on hand. The study compared 365 and 238 patients, and its lead author was at a benefits company.24

How the federal rule on copay help moved twice, and what stands today

The federal text is 45 CFR 156.130(h). It has changed through HHS's yearly payment notice, the rule that sets terms under the Affordable Care Act.25

What stands today is awkward. On December 22, 2023 the same court said that vacating the 2021 text reinstated the 2020 notice, and it expressed no view on how to read that notice or on enforcement. The agencies had told the court they meant to address the issue through rulemaking and to refrain from "any enforcement action against issuers or plans based on their treatment of such manufacturer assistance" until a new final rule.26

We found no such rule as of November 3, 2026. CMS's pre-publication copy of the final 2027 payment notice, issued May 15, 2026, has no text on 156.130(h), coupons or manufacturer assistance, by our word search of it.28 We read the agencies' position as the court quotes it. HHS's own web pages were not read. The 2025 payment notice addressed drugs classified outside essential benefits for individual and small group plans, and advocates say the promised extension to large group and self-funded plans has not arrived.23

IQVIA's patient counts, reported by Drug Channels for 2024: about one in ten patients on brand drugs for autoimmune conditions or multiple sclerosis faced an accumulator, one in four cancer patients. Maximizers grew from 4% to 6% of patients in 2019 to 13% to 24% in 2024.1 The count of 26 states is Drug Channels' as of January 2026. We found no later state as of November 3, 2026, and did not read NCSL's list.

Why a Medicare patient never gets the copay card: the kickback rule, the $2,400 cap for 2027 and the routes left

In shortA manufacturer's copay coupon implicates the federal anti-kickback statute, the law against paying to induce business from federal health programs, when a federal program pays for the drug. So hubs do not offer it to Medicare or Medicaid patients. They point to the Part D cap, the monthly payment plan, independent charities and free-drug programs, and a second person often checks the route. Part D's numbers change in January.

OIG, the Inspector General's office at the Department of Health and Human Services, put it plainly in September 2014: coupons "constitute remuneration offered to consumers to induce the purchase of specific items", and when a federal program may pay, "the anti-kickback statute is implicated". The offerors "ultimately bear the responsibility".2 A claim tied to a violation is also a false claim under the False Claims Act.2 So the first check on any summary is simple, and it has to be right every time: what kind of plan is this?

The routes a hub can name for a federal program patient

How the monthly payment plan works, with numbers

The federal rule sets the first month's cap: the annual threshold, minus costs already incurred, divided by the months left in the plan year (42 CFR 423.137).30

A patient who opts in for January 2027 with nothing incurred has a first-month cap of $2,400 ÷ 12, which is $200. So a person facing the whole $2,400 on a first fill pays no more than $200 that month and is billed the rest over the following months. Someone joining in July with $1,200 incurred has ($2,400 − $1,200) ÷ 6, also $200. The rule's own example, for 2025, uses $166.67.30

A hub's script should name options and leave the choice to the patient and the foundation.

Checking benefits for an infused drug: buy and bill, J-codes, pre-determination and site of care

In shortWhen a clinic buys and gives a drug, the plan's medical benefit pays, and the questions change. Which code? Who buys the drug? Is prior authorization required, or a pre-determination, which is something else? Where may the infusion happen? A hub that treats it like a pharmacy case will get it wrong.

Our own description of typical practice, and plans differ. Some drugs start as a clinic infusion and continue at home, so both columns can apply to one patient.

Two words get confused on a medical check. A pre-determination is an optional request to learn how a plan would treat a service in advance. Prior authorization is a required approval. A check that answers "pre-determination not required" has answered a different question.

In a second fictional case, a woman starts an infused Crohn's disease drug, Dravenzo, at Northgate GI Infusion Center under Cobalt Ridge HMO. The medical eBV says "Pre-determination not required". The plan's policy MP-418 requires prior authorization for code J3590, and the rep confirms it. The specialist settles it in favor of the policy and the call.

Annual reverification: why every patient on therapy needs a fresh check when plans renew on January 1

In shortPlans renew in January, deductibles reset and formularies change, and patients change plans. So hubs recheck their whole base of patients at once, while many plans have not yet published the new year's terms. Vendors report spikes and costs of their own; no independent figure exists.

Every January the numbers on a summary go stale together. A patient who had met a $2,500 deductible by October owes it all again. A drug can move tier. A plan may switch from an accumulator to a maximizer. Prior authorizations reach their end dates. For Part D, the cap and deductible rise on January 1 by amounts CMS published the previous April.29 A patient who reaches the pharmacy in the first week of January meets all of these at once.

What vendors say about the January reverification surge

We found no independent study of reverification volume or cost. Count your own: how many checks, how many hours and how many free-drug shipments in the first six weeks of last year.

From stale eBV data to a false statement made to a plan: the ten errors that break a benefits check

In shortNo inspector audits benefit verification in the way FDA inspects a factory, so the failures show up as rejected fills, surprise bills and, at the far end, enforcement. Most errors come from a value taken from the wrong source, or a rule read too quickly. The worst come from pressure to get a claim paid.

Our own classification; no published study ranks these. Rates for your program come from your own sent-back records.

Two enforcement lines for a hub: what you tell a plan, and what free help you give

The first line concerns what a company tells insurers. In June 2019 the Justice Department (DOJ) announced a $225 million resolution with Insys Therapeutics. It said the United States had alleged, among other things, that the company "lied to insurers about patients' diagnoses in order to obtain reimbursement" for prescriptions written for Medicare and TRICARE (military health program) patients. An Insys subsidiary agreed to plead guilty to mail fraud.40 A diagnosis stated to a plan must come from the record.

The second line is about free services. OIG's site now lists its 2003 guidance for drug makers in an archive, and we found no newer version for drug makers on November 3, 2026. That guidance says reimbursement support with no substantial independent value, standing alone, "may not implicate the anti-kickback statute". Coupled with something that benefits a referring provider, such as "a reimbursement guarantee that eliminates normal financial risks", it "would raise kickback concerns".41 Hubs keep their support tied to the product and their statements free of promises.

Who walks away from a new prescription: abandonment by out-of-pocket cost and by rejected claim

In shortTwo published lines of evidence show why accurate benefit values matter. Patients abandon new prescriptions as their cost rises. And nearly half of prescriptions rejected for prior authorization end up denied. Neither measures benefit verification itself, so your own program's data has to close that gap.

IQVIA reports the same pattern more broadly: abandonment for branded medicines is about 10% when the patient owes nothing and approaches 60% above $250. It also reports that the share of commercial patients with no out-of-pocket exposure fell from 34% in 2020 to 29% in 2025.43 An older study, from a pharmacy benefit manager's data, found patients far less likely to abandon biologic anti-inflammatory and multiple sclerosis drugs when coupons brought monthly cost sharing below $250.44

Physicians report the same strain. In the American Medical Association's survey of 1,000 physicians, published in December 2025, 95% reported delays, 79% said prior authorization at least sometimes leads patients to abandon treatment, and practices handled about 40 requests per physician per week, taking 13 hours of physician and staff time. We read the survey's results in two reports, Texas Medicine and Medical Economics, which agree.46,47

Who sells benefit verification and what they claim: faster eBVs, AI callers and turnaround numbers that do not compare

In shortHub vendors, eBV networks and voice-call companies all sell into this work. Their published numbers are their own, measure different things and rarely mention accuracy. There is no public figure for the size of the market. Read every claim with its base.

Much of what a buyer can read about turnaround comes from three kinds of company. Each number below is true to its own definition, and none can be set beside another.

Three trends add to the work. Coverage keeps getting stricter: our coverage tracking guide gives the numbers. More patients face a cost: IQVIA reports commercial out-of-pocket spending up roughly 37% since 2020 and an out-of-pocket maximum of $12,000 for one person on an Affordable Care Act (ACA) plan in 2027.43 Part D coinsurance on specialty drugs runs at a median of 28% in Medicare Advantage drug plans and 25% in stand-alone plans in 2026.6 All of these raise the number of values that have to be right.

Market size for hub benefit verification: no public figure we could verify. Market research firms sell estimates, and we read none we could trace. Provider-side checks, a far larger and different market, cost medical providers and plans $44 billion in 2023, by CAQH's count.5

AI can sit on hold and cite every line of a benefits check; settling a disagreement stays with people

In shortSoftware can read sources, cite lines, compare values, draft from templates and sit on hold. It should not settle a disagreement, choose a route for a federal patient or tell anyone a plan will pay. Most AI guidance written for drug makers does not reach this work, so the controls have to come from your own program.

FDA's draft, Annex 22, the EU AI Act, HIPAA and the TCPA: which touch a hub's benefit checks, as of November 2026

Today's benefits check: the specialist, case manager, office and compliance reviewer who pass one case along

In shortA small chain of people passes one case along, usually over one to two days. Most of the elapsed time goes to reaching the plan and reading sources. Teams run this in house, through a hub vendor, or with software. No public survey shows how the hours split.

Choosing who runs benefit checks: your own staff, a hub vendor or software on either

Systems involved: a clearinghouse or eBV network, phone and call recording, a plan document library, payer portals, a hub case system (often customer relationship management software), a fax and office portal, and letter templates. The people and steps above are our own description of common practice.

Five sources, four disagreements, one accumulator and a release at 17 hours: Jordan Ellis's benefits case

In shortThis is the example from the top of the page, inside the product. Six agents gather and read the evidence, compare it and draft. Dana Okafor, the benefits specialist, settles every difference and signs. Sam Patel, the case manager, takes the next steps. No agent decides a value or sends anything.

1

Five sources arrive before anyone reads them

The office enrolled Jordan at 4:20 pm on October 6. By the next morning the case holds the hub record, the pharmacy eBV, a 14-minute call transcript, the formulary's July 1 update and a capture of the portal's criteria. The clock reads 17 hours of a 48-hour promise.

The eBV reads cleanly: tier 4, $50, no PA, no step. Its "benefit data as of" line says June 15, 2026. Nothing is built until someone asks.

2

The hub record shows consent and what the office sent

The record carries the diagnosis, body surface area, prior therapy, prior biologics and insurance details, and the patient's HIPAA authorization, signed October 6. It is the base for the criteria check in step 5, and for the question of who may see what.

3

"Build the summary" quotes both sides of every disagreement

Dana presses one button. Six values agree and carry their citations. Four turn amber: tier, cost, prior authorization and step therapy. On prior authorization the screen sets the eBV's "Not required" beside the rep's words at 05:05: "Prior authorization is required: moderate-to-severe plaque psoriasis, at least 10 percent body surface or hands, feet, face or genitals, and 12 weeks of a conventional systemic."

Below the quotes is the reason: the plan added prior authorization when Veltrimab moved to tier 5 on July 1, and the eBV answers from June data. A click on any citation opens that exact line in the transcript.

4

Dana settles all four, and confirms the flag the eBV never reported

She chooses the newest dated source for each: tier 5 since July 1, 30% after the deductible up to $250 a fill, prior authorization required, one preferred biologic first. Each choice records what it overrode. Then she confirms the copay accumulator: help from the Northwind copay program will not count toward Jordan's $2,500 deductible or $6,800 out-of-pocket maximum. The rep said so at 09:11, and the formulary names a copay adjustment program.

5

The criteria check finds three of four met, and says nothing about approval

The plan rules reader turns the portal criteria into a checklist and looks for each in the hub record: L40.0 on the form, 14% body surface recorded September 29, 16 weeks of methotrexate. The fourth, one preferred biologic first, is unmet, so the office should ask for a step therapy exception with the reason. The screen does not predict what the plan will do.

6

The office summary and the letter come from templates

The office copy lists eleven values, each numbered to its source, with three next steps at the top and the call reference. Its closing statement says the investigation does not guarantee coverage or payment. Jordan's letter comes from template PL-04 v3. The compliance checker passes it first: reading grade 5.8 against a limit of 6, approved template, the no-promise sentence, no diagnosis named, and copay wording allowed for a commercial plan.

7

She signs, and the next steps go to the case manager

Release sends the summary to the office by portal and fax, the letter to Jordan in English, and five tasks to Sam Patel. Dana signs, and the record keeps what her signature means, her name and the date. The record shows release at 9:55 am on October 7, about 17 hours after the request.

The tasks: help the office submit PA through the portal, due October 9; a step therapy exception with Dr. Moreno; a referral to Tollmere Specialty Pharmacy; copay enrollment, planning the year around the accumulator; and a call to Jordan. A reverification reminder is set for December 1.

The solution's design targets are a median under 20 hours from request to released summary against a 48-hour promise, and 95% of summaries accepted by the office the first time. Those are targets to measure on your own cases. The 17 hours and the amounts belong to this sample.

A hub's other benefit cases on screen: an infused drug, a maximizer, Medicare, an excluded drug and the January wave

In shortOne clean case makes a good story, and a real queue holds many kinds. These screens show the others: a medical-benefit case where the words differ, a maximizer, a federal plan with no copay program, a drug off the formulary, a case still waiting on the plan, a letter in Spanish, the audit trail, the January forecast, the dashboard and the settings.

The benefits specialist settles and signs every release; six agents gather, read and draft

In shortEach agent does one job and has a written limit. People settle each difference and sign each release, and a second person checks each federal-plan route. Every step goes on the record.

The named person behind every settled value, signed release and approved template

Enterprise controls: roles and separation of duties, maker-checker on every release, a second check for federal plans, an exportable audit trail, and connections to your clearinghouse, call platform and hub system. These controls support your own HIPAA and anti-kickback programs. Your counsel decides whether they meet your obligations. Botminds is SOC 2 Type II audited and manages information security to ISO 27001. This is commercial work, outside GxP scope.

What a benefits case needs from the plan and your hub, and what it hands back

Your clearinghouse, call platform and hub system: what flows to and from each

Rejected first fills, free-drug bridges, sent-back cases, patients who never start: the price of a wrong benefits summary

In shortPublic data shows how strongly cost and rejection drive patients away. It cannot tell you what your own errors cost, because nobody publishes that. A week with your own case records will. Six numbers cover most of it.

Where a wrong benefits summary hides its cost, and the record that reveals each one in a week

What no benefits calculator counts: a lost office, one Medicare coupon, a specialist who quits

The payback on cited benefit checks, counted in specialist hours, sent-back cases and therapy starts

In shortPut in your own numbers. The calculator counts specialist time, fewer sent-back cases, a share of therapy starts kept and the January wave. Every default is an assumption to replace, because no public benchmark exists for any of them.

The formulas behind a hub's return: specialist time, rework, therapy starts, the January peak

Run your hub's numbers: investigations, send-backs, starts at risk and January rechecks

Score your hub before automating benefit checks: baselines, federal plans, contracts and January

In shortScore each question from 0 to 2. The result says whether to build your baseline first, run a pilot, or plan the rollout. Your answers stay on this page.

Nineteen questions to put to a benefit verification vendor on accuracy, disagreements, federal plans and patient data

In shortMost demos look alike on a clean commercial case. These questions separate them on the hard ones: a stale eBV, a medical-benefit word trap, a Medicare patient and a payer that hangs up. Ask us too.

Piloting benefit verification software in 12 weeks: two products, your ten busiest payers, one gold set

In shortStart where the volume is, with cases you have already closed. Build a gold set from past cases, run in parallel against your current process, measure and decide. Keep the people who settle and sign exactly as they are today. If you can, finish before your January wave or start right after it.

The six numbers that decide the pilot, from accuracy per value to zero copay offers on federal plans

Benefits investigation FAQ: eBV disagreements, copay accumulators, Medicare copay cards and HIPAA

In shortFourteen short answers on what the work is, which rules apply and how far software can be trusted with it.